REGENXBIO Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 7.41 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 489.16M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Details
| Name | REGENXBIO Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 371 |
| Founded | 2008 |
| Ipo Date | 2015-09-17 |
| Ceo | Curran Simpson |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US75901B1070 |
| Cusip | 75901B107 |
| Cik | 0001590877 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Dr. Stephen Pakola M.D. | Executive Vice President and Chief Medical Officer |
| Mitchell Chan M.B.A. | Executive Vice President and Chief Financial Officer |
| Craig Malzahn | Executive Vice President of Product Development and Chief Technology Officer |
| Dr. Olivier Danos Ph.D. | Executive Vice President and Chief Scientific Officer |
| Dr. Ram Palanki Pharm.D. | Executive Vice President and Chief Commercial Officer |
| Dr. Jahannaz Dastgir D.O. | Clinical Development Lead |
Contact
| Address | 9804 Medical Center Drive, Rockville, Maryland 20850, United States |
| Phone | 240 552 8181 |
| Website | https://www.regenxbio.com |